After the July 13, 2026 FDA decision, people with mild cognitive impairment can start Leqembi (lecanemab), an early-Alzheimer's treatment, at home or by IV. The at-home start is 500 mg weekly as two 250-mg autoinjector shots for initiation through maintenance, according to the Eisai/Biogen press release at-home dosing approval.
Mild cognitive impairment means thinking changes that are noticeable but do not block daily tasks. Home dosing changes where treatment happens, not the need for brain scans and clinician oversight. The choice turns on home support, clinic access, and comfort with shots versus infusions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Apply through Multivu’s official page — Use this page to review requirements and apply directly.
Table of Contents
- Who is Leqembi for?
- How do home shots and clinic infusions compare?
- What safety risks stay the same?
- What monitoring does home dosing still require?
Who is Leqembi for?
Leqembi is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease with confirmed amyloid pathology, according to the Alzheimer's Association treatment guide. Amyloid means protein buildup tied to Alzheimer's.
A clinician must confirm the cause of memory change and test for amyloid before prescribing. People with later-stage dementia, other causes of impairment, or unconfirmed amyloid are outside the approved group.
How do home shots and clinic infusions compare?
The IV start remains weight-based 10 mg/kg every two weeks as an about one-hour infusion, and patients may switch routes under clinician direction, according to the Eisai/Biogen press release. The subcutaneous path uses a fixed weekly dose at home after training.
The home approval relied on matching drug exposure and similar amyloid removal to IV, not a new 18-month outcomes trial, according to a Drug Topics report. IV benefit came from Clarity AD, which showed slower decline on a dementia rating scale at 18 months.
- At home: one weekly session with two autoinjector shots, given by patient or caregiver after training.
- In clinic: one infusion visit every two weeks for starting treatment, with staff present.
- Either path: clinician decides dose changes, pauses, and route switches.
What safety risks stay the same?
Leqembi carries an FDA Boxed Warning for amyloid-related imaging abnormalities with swelling, called ARIA-E, and bleeding, called ARIA-H, according to Eisai safety information safety information. Testing for APOE ε4 is recommended because people with two copies face higher ARIA risk.
Bleeding risk needs review when blood thinners are used. Home shots tend to cause local skin reactions where the needle enters. Clinic infusions carry a higher chance of body-wide infusion reactions during or soon after the drip, according to a Medscape report.
What monitoring does home dosing still require?
Home dosing does not drop MRI checks, training, or clinician follow-up. FDA recommended an extra earlier MRI before the third infusion to catch swelling sooner, plus a baseline scan and periodic scans when risk is highest, according to an FDA safety communication MRI monitoring update.
Bring a list of blood thinners, fall history, and headache, vision change, or confusion episodes to each visit. Ask your clinician to confirm MRI dates and blood-thinner review before the first home dose.
- Complete baseline MRI and early follow-up scans on schedule.
- Finish caregiver injection training before the first home dose.
- Keep clinician visits for ARIA review, blood-thinner checks, and reaction counseling.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: Safety and Monitoring Questions for People With Mild Cognitive Impairment
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: Questions People With Mild Cognitive Impairment Can Ask an Alzheimer’s Specialist
- The WHO 45% Modifiable Dementia Risk Estimate in 2026: Questions Adults Over 65 Can Discuss With a Clinician
